AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Files An 8-K Regulation FD DisclosureItem 7.01. Regulation FD Disclosure.
On November 28, 2016, Amicus Therapeutics, Inc. (the “Company”) hosted a conference call and webcast to discuss the U.S. Regulatory Pathway for Migalastat for Fabry Disease.
Item 8.01. Other Events.
On November 28, 2016, the Company issued a press release announcing the U.S. Regulatory Pathway for Migalastat for Fabry Disease. A copy of this press release is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K and the Exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits: The Exhibit Index annexed hereto is incorporated herein by reference.